Rocket Pharmaceuticals Advances RP-A501 Toward Danon Disease Approval
CRANBURY, N.J. — September 15, 2026 Rocket Pharmaceuticals, Inc. announced alignment with the U.S. Food and Drug Administration (FDA)...
Cardiomyopathy
Advertisement
Tenaya Therapeutics Gains RMAT Designation for TN-401
SOUTH SAN FRANCISCO, Calif. — September 14, 2026 Tenaya Therapeutics, Inc. announced that the U.S. Food and Drug Administration...
Alnylam Presents ATTR-CM Data at ESC Congress 2026
Cambridge, Mass. – August 30, 2026 Alnylam Pharmaceuticals announced new clinical data at the European Society of Cardiology (ESC)...
ArkBio Completes Phase I Dosing of AK0406 Influenza Drug
SHANGHAI, July 23, 2026 ArkBio has successfully completed dosing across all cohorts in its Australian Phase I clinical trial...
Lundbeck Wins FDA Fast Track for Lu AH69593 in Narcolepsy
VALBY, Denmark, July 23, 2026 Lundbeck has received U.S. Food and Drug Administration (FDA) Fast Track designation for Lu...
Advertisements
Royalty Pharma Acquires Cliramitug Royalty Rights from Neurimmune
NEW YORK, July 22, 2026 Royalty Pharma plc has announced the acquisition of a portion of Neurimmune’s royalty interest...
Akeso Opens U.S. Phase II Trial for PD-1/CTLA-4 Bispecific
HONG KONG, July 14, 2026 Akeso, Inc. has announced the launch of a Phase II clinical trial in the...
HitGen Partner BioAge Launches Phase II Trial for BGE-102
CHENGDU, China, July 14, 2026 HitGen Inc. has announced that its partner BioAge Labs has dosed the first participant...
Atrium Therapeutics Launches Phase 1/2 Trial for ATR 1072
SAN DIEGO, Calif., July 14, 2026 Atrium Therapeutics has achieved an important regulatory milestone after the U.S. Food and...
Tenaya Gene Therapy Shows Strong Arrhythmia Reduction in ARVC Trial
SOUTH SAN FRANCISCO, Calif., May 15, 2026 Tenaya Therapeutics reported encouraging interim Phase 1b/2 clinical data for TN-401, its...
Advertisement
